These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 26586732

  • 1. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM.
    J Am Heart Assoc; 2015 Nov 19; 4(11):. PubMed ID: 26586732
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
    Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U.
    BMC Cardiovasc Disord; 2014 Sep 20; 14():121. PubMed ID: 25240705
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2344-53. PubMed ID: 22463922
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM.
    Am Heart J; 2015 Jun 19; 169(6):906-915.e13. PubMed ID: 26027630
    [Abstract] [Full Text] [Related]

  • 5. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJ.
    J Am Heart Assoc; 2016 Jun 10; 5(6):. PubMed ID: 27287699
    [Abstract] [Full Text] [Related]

  • 6. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H, Gumbiner B, Joh T, Riel T, Udata C, Forgues P, Garzone PD.
    Clin Ther; 2017 Nov 10; 39(11):2243-2259.e5. PubMed ID: 29037448
    [Abstract] [Full Text] [Related]

  • 7. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 8. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 9. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA.
    J Am Coll Cardiol; 2012 Nov 06; 60(19):1888-98. PubMed ID: 23083772
    [Abstract] [Full Text] [Related]

  • 10. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 11. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
    Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS.
    Clin Cardiol; 2012 Nov 13; 35(7):385-91. PubMed ID: 22714699
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M, ODYSSEY CHOICE II Investigators.
    J Am Heart Assoc; 2016 Sep 13; 5(9):. PubMed ID: 27625344
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
    Teramoto T, Kiyosue A, Ishigaki Y, Harada-Shiba M, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M.
    J Cardiol; 2019 Mar 13; 73(3):218-227. PubMed ID: 30509509
    [Abstract] [Full Text] [Related]

  • 16. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.
    Am Heart J; 2014 Nov 13; 168(5):682-9. PubMed ID: 25440796
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.
    Cardiovasc Ther; 2018 Feb 13; 36(1):. PubMed ID: 29078037
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
    Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y.
    Diabetes Obes Metab; 2017 Jul 13; 19(7):989-996. PubMed ID: 28206704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.